Hepion Pharmaceuticals Stock Today
| HEPA Stock | USD 0.80 0.03 3.61% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Hepion Pharmaceuticals is trading at 0.8 as of the 22nd of March 2025, a 3.61 percent decrease since the beginning of the trading day. The stock's open price was 0.83. Hepion Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of February 2014 | Category Healthcare | Classification Health Care |
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey. The company has 1.08 M outstanding shares of which 4.75 M shares are currently shorted by private and institutional investors with about 0.17 trading days to cover. More on Hepion Pharmaceuticals
Moving together with Hepion Stock
| 0.62 | DSGN | Design Therapeutics | PairCorr |
| 0.9 | EYEN | Eyenovia | PairCorr |
| 0.89 | CGC | Canopy Growth Corp | PairCorr |
| 0.61 | MRK | Merck Company | PairCorr |
Moving against Hepion Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Hepion Stock Highlights
| Executive Chairman | John CPA | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsHepion Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Hepion Pharmaceuticals' financial leverage. It provides some insight into what part of Hepion Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Hepion Pharmaceuticals (HEPA) is traded on NASDAQ Exchange in USA. It is located in 399 Thornall Street, Edison, NJ, United States, 08837 and employs 22 people. Hepion Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 895.32 K. Hepion Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 1.08 M outstanding shares of which 4.75 M shares are currently shorted by private and institutional investors with about 0.17 trading days to cover.
Hepion Pharmaceuticals currently holds about 59.15 M in cash with (40.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.78.
Check Hepion Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationRoughly 96.57 (percent) of Hepion Pharmaceuticals outstanding shares are held by general public with 1.95 % owned by insiders and only 1.48 pct. by outside corporations.
Check Hepion Ownership Details
Hepion Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Federation Des Caisses Desjardins Du Quebec | 2024-12-31 | 175 | |
| Sbi Securities Co Ltd | 2024-12-31 | 125 | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 113 | |
| Group One Trading, Lp | 2024-12-31 | 84.0 | |
| Bank Of America Corp | 2024-12-31 | 57.0 | |
| Barclays Plc | 2024-12-31 | 16.0 | |
| Hanson Mcclain Inc | 2024-12-31 | 2.0 | |
| Northern Trust Investments N A | 2024-12-31 | 0.0 | |
| Advisornet Financial, Inc | 2024-12-31 | 0.0 | |
| Anson Funds Management Lp | 2024-12-31 | 231.8 K | |
| Blackrock Inc | 2024-12-31 | 83 K |
Hepion Pharmaceuticals Historical Income Statement
Hepion Stock Against Markets
Hepion Pharmaceuticals Corporate Management
| BSc BSc | CEO Pres | Profile | |
| Patrick Mayo | Senior Pharmacology | Profile | |
| John Cavan | Chief Officer | Profile | |
| Sharen Pyatetskaya | Director Relations | Profile | |
| Todd MD | Chief Officer | Profile | |
| Daniel Trepanier | Senior Development | Profile | |
| Daren Ure | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.